LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
Halozyme Therapeutics
HALO
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
YETI Holdings
YETI
Dorian LPG
LPG
US Stock MarketDetailed Quotes
NBY NovaBay Pharmaceuticals
- 0.5766
- +0.0098+1.73%
Close Dec 27 16:00 ET
- 0.5601
- -0.0165-2.86%
Post 20:01 ET
2.82MMarket Cap-0.01P/E (TTM)
0.6000High0.5570Low186.92KVolume0.5570Open0.5668Pre Close106.13KTurnover3.83%Turnover Ratio0.00P/E (Static)4.89MShares9.079052wk High2.64P/B2.81MFloat Cap0.361152wk Low--Dividend TTM4.88MShs Float130156.1979Historical High--Div YieldTTM7.59%Amplitude0.3610Historical Low0.5670Avg Price1Lot Size
NovaBay Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -1.61%2.44M | -32.09%2.4M | 12.48%2.63M | 2.24%14.73M | 74.91%6.37M | -35.15%2.48M | -3.50%3.53M | -28.54%2.34M | 41.16%14.4M | 14.81%3.64M |
| Operating revenue | -1.90%2.42M | -32.25%2.39M | 12.52%2.62M | 2.18%14.69M | 75.19%6.36M | -35.25%2.47M | -3.74%3.52M | -28.62%2.33M | 41.20%14.37M | 14.61%3.63M |
| Cost of revenue | 3.54%848K | -54.99%808K | 13.26%837K | 3.14%6.83M | 84.22%3.48M | -43.56%819K | -1.59%1.8M | -49.35%739K | 79.53%6.62M | 26.29%1.89M |
| Gross profit | -4.15%1.59M | -8.45%1.59M | 12.13%1.79M | 1.47%7.9M | 64.90%2.89M | -30.02%1.66M | -5.39%1.74M | -11.80%1.6M | 19.43%7.78M | 4.59%1.76M |
| Operating expense | 12.46%2.65M | -5.20%2.65M | 14.26%3.37M | -16.58%12.9M | 8.08%4.8M | -16.67%2.36M | -30.08%2.79M | -29.81%2.95M | 0.55%15.46M | -8.78%4.44M |
| Selling and administrative expenses | 12.48%2.65M | -4.77%2.64M | 14.00%3.35M | -16.07%12.83M | 8.98%4.77M | -15.59%2.36M | -29.92%2.77M | -29.58%2.94M | -0.30%15.29M | -9.99%4.38M |
| -Selling and marketing expense | -25.02%947K | -13.28%1.02M | -14.64%1.06M | -16.65%6.5M | 45.82%2.83M | -31.17%1.26M | -42.40%1.18M | -37.35%1.24M | -3.65%7.8M | -9.90%1.94M |
| -General and administrative expense | 55.81%1.7M | 1.51%1.62M | 34.84%2.29M | -15.48%6.33M | -20.29%1.95M | 14.33%1.09M | -16.60%1.59M | -22.60%1.7M | 3.44%7.49M | -10.06%2.44M |
| Research and development costs | 0.00%4K | -59.09%9K | 90.00%19K | -60.92%68K | -51.52%32K | -90.24%4K | -45.00%22K | -64.29%10K | 295.45%174K | 725.00%66K |
| Operating profit | -52.01%-1.06M | -0.19%-1.05M | -16.80%-1.57M | 34.86%-5M | 29.01%-1.91M | -52.74%-698K | 51.16%-1.05M | 43.53%-1.35M | 13.34%-7.68M | 15.81%-2.69M |
| Net non-operating interest income expense | 78.93%-138K | 40.12%-300K | -433K | -655K | -501K | 0 | ||||
| Non-operating interest expense | -78.93%138K | -40.12%300K | --433K | ---- | ---- | --655K | --501K | --0 | ---- | ---- |
| Other net income (expense) | -13K | -31.82%-232K | -1.09M | -58.37%-4.64M | 19.14%-4.46M | -5,766.67%-176K | -196.38%-2.93M | -281.72%-5.52M | ||
| Gain on sale of security | ---- | -163.67%-163K | --259K | -99.43%20K | -124.18%-236K | ---- | --256K | ---- | -23.64%3.52M | --976K |
| Special income (charges) | ---13K | --0 | ---865K | 58.01%-2.59M | 59.45%-2.59M | --0 | --0 | --0 | ---6.18M | ---6.4M |
| -Less：Restructuring and merger&acquisition | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---561K | ---342K |
| -Less:Impairment of capital assets | ---- | ---- | ---- | -61.51%2.59M | ---- | ---- | ---- | ---- | --6.74M | ---- |
| -Less:Other special charges | --13K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Gain on sale of business | --0 | --0 | ---865K | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Other non- operating income (expenses) | ---- | 84.03%-69K | ---480K | -647.83%-2.06M | -1,565.31%-1.63M | ---- | -14,300.00%-432K | ---- | 82.50%-276K | 93.79%-98K |
| Income before tax | 10.42%-1.21M | 8.28%-1.59M | -129.74%-3.09M | 9.13%-9.64M | 36.46%-5.21M | -894.85%-1.35M | 19.81%-1.73M | -1,111.71%-1.35M | -82.14%-10.61M | -5,093.67%-8.21M |
| Income tax | ||||||||||
| Net income | 31.02%-1.21M | 22.15%-1.59M | -84.82%-3.21M | 9.13%-9.64M | 49.94%-4.11M | -1,191.91%-1.76M | 5.52%-2.04M | -1,466.67%-1.74M | -82.14%-10.61M | -5,093.67%-8.21M |
| Net income continuous Operations | 10.42%-1.21M | 8.28%-1.59M | -129.74%-3.09M | 9.13%-9.64M | 36.46%-5.21M | -894.85%-1.35M | 19.81%-1.73M | -1,111.71%-1.35M | -82.14%-10.61M | -5,093.67%-8.21M |
| Net income discontinuous operations | --0 | --0 | 68.53%-124K | ---- | ---- | ---404K | ---308K | ---394K | ---- | ---- |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 31.02%-1.21M | 22.15%-1.59M | -84.82%-3.21M | 9.13%-9.64M | 49.94%-4.11M | -1,191.91%-1.76M | 5.52%-2.04M | -1,466.67%-1.74M | -82.14%-10.61M | -5,093.67%-8.21M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | 1.01M | 0 | 380K | 24.75%7.06M | 5.06M | 0 | 2M | 0 | 5.66M | 0 |
| Net income attributable to common stockholders | -26.18%-2.22M | 60.69%-1.59M | -106.67%-3.59M | -2.66%-16.7M | -11.74%-9.17M | 69.67%-1.76M | -87.10%-4.03M | -1,466.67%-1.74M | -147.98%-16.27M | -818.92%-8.21M |
| Basic earnings per share | 95.42%-0.6 | 96.92%-1.37 | 82.35%-5.25 | 60.79%-138.6 | 82.92%-28.5762 | 89.62%-13.11 | 11.23%-44.43 | -962.50%-29.75 | -92.02%-353.5 | -573.24%-167.3 |
| Diluted earnings per share | 95.42%-0.6 | 96.92%-1.37 | 82.35%-5.25 | 60.79%-138.6 | 82.92%-28.5762 | 89.62%-13.11 | 11.23%-44.43 | -962.50%-29.75 | -92.02%-353.5 | -573.24%-167.3 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |